283 related articles for article (PubMed ID: 2418688)
1. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
2. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
4. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
5. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
[TBL] [Abstract][Full Text] [Related]
6. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
7. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
Dejmek A; Hjerpe A
Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
[TBL] [Abstract][Full Text] [Related]
8. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
Stahel RA; O'Hara CJ; Waibel R; Martin A
Int J Cancer; 1988 Feb; 41(2):218-23. PubMed ID: 3276635
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
11. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
12. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
Otis CN; Carter D; Cole S; Battifora H
Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
[TBL] [Abstract][Full Text] [Related]
14. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
16. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
17. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
Loosli H; Hurlimann J
Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
Holden J; Churg A
Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
[TBL] [Abstract][Full Text] [Related]
19. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies.
Noguchi M; Nakajima T; Hirohashi S; Akiba T; Shimosato Y
Hum Pathol; 1989 Jan; 20(1):53-7. PubMed ID: 2912874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
